All News #Library
Biotech
Vyome Shares Phase 2 VT-1953 Clinical Data at AACR 2026
22 Apr 2026 //
BUSINESSWIRE
Vyome Publishes Positive Preclinical Results For Uveitis
18 Feb 2026 //
BUSINESSWIRE
Independent Analyst Values Vyome`s VT-1953 At $1B Post Phase 3
27 Jan 2026 //
BUSINESSWIRE
Vyome Reports Positive Final Phase 2 Results for VT-1953
08 Dec 2025 //
BUSINESSWIRE
Vyome Holdings Unveils Game-Changing Q1 Post Nasdaq Listing
18 Nov 2025 //
BUSINESSWIRE

Market Place
Sourcing Support